Refine by
Covid 19 Sars Cov 2 Antigen Articles & Analysis
12 news found
Today, the Baker-Polito Administration announced that more than $1.5 million has been awarded to four projects that seek to increase testing capacity and provide solutions for coronavirus testing. The funding is through the Accelerating Coronavirus Testing Solutions (A.C.T.S.) Program, designed and administered by the Massachusetts Life Sciences Center, which supports projects focused on two core ...
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical ...
Quidel Corporation (NASDAQ: QDEL) (“Quidel”),a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million. COVID-19 ...
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its ...
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that following completion of the of US performance studies, its technology partner, Mologic Ltd (“Mologic”) has filed its submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its rapid point-of-care COVID-19 antigen ...
AZOVA Inc., creator of the world’s most comprehensive digital health network for COVID-19 testing and vaccination management, and Ellume, the company to bring the first non-prescription over-the-counter COVID-19 home test to market, today announced an official partnership with Alaska Airlines to provide a convenient, at-home rapid testing solution for its passengers. The Ellume COVID-19 ...
The Company remains in regular dialogue with the Department of Health and Social Care ("DHSC") to provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose. Omega is still waiting for confirmation on which test it will be required to manufacture. Omega is not in control of this process ...
CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), today announced the availability of three over-the-counter COVID-19 testing options in stores and online. The tests include the Ellume COVID-19 Home Test, the Abbott BinaxNOW COVID-19 Antigen Self Test and the Pixel by Labcorp PCR Test Home Collection Kit. All three tests have received FDA Emergency Use Authorization (EUA), do not ...
iXensor, the pioneer of mobile health, today announced its “PixoTest® COVID -19 Antigen Self-Test Kit” has been granted by Taiwan FDA for EUA, in response to the recent peak of the epidemic and the new quarantine mandate of 0+7 taking effect on Oct 13th, Taiwan will officially enter the era of “self-initiated epidemic prevention”. The latest study of variant ...
ByiXensor
Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), to complete the development and launch of a new test for Zika virus infection. Kephera’s test is aimed at detecting Zika ...
As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones are facing today, creating, manufacturing, testing, and delivering ...